Chemomab Therapeutics (CMMB) Assets Average (2019 - 2025)
Chemomab Therapeutics' (CMMB) quarterly Assets Average came in at $13.1 million in Q4 2025, down 30.85% YoY from $18.9 million in Q4 2024, and up 11.42% on a QoQ basis from $11.7 million in Q3 2025.
Chemomab Therapeutics (CMMB) Assets Average (2019 - 2025) Analysis & Trends
Chemomab Therapeutics (CMMB) has 7 years of Assets Average data on file, last reported at $13.1 million in Q4 2025.
- Quarterly Assets Average fell 30.85% year-over-year to $13.1 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $13.1 million (down 30.85% YoY) and the FY2025 annual result came in at $15.4 million, down 21.32% from the prior year.
- Assets Average climbed to $13.1 million in Q4 2025, from $11.7 million in the prior quarter.
- In the past five years, Assets Average ranged from a high of $69.0 million in Q3 2021 to a low of $11.7 million in Q3 2025.
- A 5-year average of $35.1 million and a median of $29.0 million in 2023 frame the typical range for Assets Average.
- Annual changes were most pronounced in 2021 — Assets Average jumped 679.2% — and 2023, when it slumped 51.15%.
- Tracing CMMB's Assets Average over 5 years: stood at $65.9 million in 2021, then dropped by 29.22% to $46.6 million in 2022, then slumped by 51.15% to $22.8 million in 2023, then fell by 16.92% to $18.9 million in 2024, then sank by 30.85% to $13.1 million in 2025.
- The last three Assets Average figures came in at $13.1 million (Q4 2025), $11.7 million (Q3 2025), and $12.0 million (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Assets Avg. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 26.95 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 41.30 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | - |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 11.22 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 8.86 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 5.34 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 2.09 Bn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 19.82 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 25.27 Bn |
| 10 | Chemomab Therapeutics | 13.33 Mn | 2.96 Mn | - | 13.09 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Dec 31, 2025 | 13.09 Mn |
| Sep 30, 2025 | 11.75 Mn |
| Jun 30, 2025 | 11.97 Mn |
| Mar 31, 2025 | 14.89 Mn |
| Dec 31, 2024 | 18.93 Mn |
| Sep 30, 2024 | 17.72 Mn |
| Jun 30, 2024 | 16.28 Mn |
| Mar 31, 2024 | 20.08 Mn |
| Dec 31, 2023 | 22.78 Mn |
| Sep 30, 2023 | 26.13 Mn |
| Jun 30, 2023 | 31.93 Mn |
| Mar 31, 2023 | 39.04 Mn |
| Dec 31, 2022 | 46.64 Mn |
| Sep 30, 2022 | 53.30 Mn |
| Jun 30, 2022 | 58.67 Mn |
| Mar 31, 2022 | 62.65 Mn |
| Dec 31, 2021 | 65.90 Mn |
| Sep 30, 2021 | 68.98 Mn |
| Jun 30, 2021 | 65.32 Mn |
| Mar 31, 2021 | 36.30 Mn |